Lenire Tinnitus Technology
Lenire (Len-ear), which is Latin for ‘soothe’, is the only commercially available, clinically trialed, dual mode tinnitus treatment device approved by the US FDA.
- Safety and effectiveness trialed with 600+ patients. 4
- Successfully trialed with real-world patients.
- Technology with over 136 worldwide patents.
- More effective than sound for moderate or worse tinnitus. 3
- At-home customized tinnitus treatment device.
- Backed and guided by healthcare professionals.
- Wireless headphones, Tonguetip and Controller included.
How Does the Lenire Tinnitus Treatment Device Work?
Watch to learn how a custom combination of audio and tongue stimulation (dual mode) can soothe tinnitus.
Relaxing Lenire Moments
Lenire soothes your tinnitus with two relaxing 30-minute sessions per day. A dual mode combination of beautiful soundscapes and tongue pulses customized to your hearing profile help your brain to stop focusing on tinnitus.
What is Dual Mode Stimulation?
Dual Mode is a form of bimodal neuromodulation. This is when two stimuli produce beneficial changes in the brain. Lenire combines audio through wireless headphones and mild pulses to the tongue to help you pay less attention to your tinnitus.
Lenire Three Step Plan
At-Home Relief from Tinnitus
Initial Tinnitus Assessment
Visit a Lenire Provider for an initial tinnitus assessment, hearing test and device fitting. Every Lenire device is customized to your tinnitus and hearing profile by trained professionals.
At-Home Lenire Moments
Use Lenire at home for two, calming 30-minute sessions per day. Attend mid-treatment check-ins with your provider to review progress and make adjustments.
Review and Continued Use
Visit your Lenire Provider to review progress and get advice on continued use if needed or desired. Many enjoy their Lenire moments and continue to use the device post-treatment.
Find a Clinic
Lenire has expert Partner Clinics across America, Europe, and the United Kingdom. Use the Lenire Clinic Map to start your treatment with Lenire.
1. TENT-A1 Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020)
2. TENT-A2: Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep.
3. TENT-A3: Clinical trial data in preparation for independent publication: clinicaltrials.gov/ct2/show/NCT05227365.
4. Aggregate: TENT-A1, TENT-A2, TENT-A3 aggregate clinical trial results.
Note 1: All statistics based on compliant patients. Patient compliance criteria is detailed in Lenire’s clinical trial design.
Note 2: TENT-A1/TENT-A2 were not considered by the United States of America FDA as part of Lenire’s FDA Grant and, as such, applies solely to outside the US.